Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

PSC 100

Drug Profile

PSC 100

Alternative Names: HPDSC; Human placenta-derived stem cells; Placental-derived stem cell therapy - Celularity; PSC-100; UCB + HPDSC; UCB and HPDSC

Latest Information Update: 28 Jul 2020

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Celgene Corporation; Human Longevity
  • Developer Celgene Corporation; Celularity; Human Longevity; New York Medical College
  • Class Stem cell therapies
  • Mechanism of Action Cell replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Phase I Haematological disorders; Haematological malignancies
  • Preclinical Epidermolysis bullosa; Inflammation
  • No development reported Muscular atrophy

Most Recent Events

  • 28 Jul 2020 No recent reports of development identified for research development in Muscle-wasting in USA (IV)
  • 20 Nov 2019 Celgene Corporation has been acquired by Bristol-Myers Squibb
  • 24 Jul 2018 Phase I development in Haematological malignancies and Haematological disorders is ongoing in USA (IV) (Celularity pipeline, July 2018)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with a username/password associated to your organization’s account.
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Federated access using single sign-on credentials.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top